Clinical Trial

Combined Kidney and Hematopoietic Stem Cell Transplantation for Tolerance Induction

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 28, 2021 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Combined transplantation of kidney and bone marrow between HLA-matched sibling donor-recipient pairs to induce immune tolerance in order to enable complete discontinuation of immunosuppressive therapy without kidney rejection. Hematopoietic stem cells are collected from the donor 4 to 8 weeks before kidney transplantation, CD34 cells are enriched by positive selection and cryopreserved. The day after kidney transplantation the recipient starts conditioning therapy with thymoglobuline, total lymphoid irradiation, steroids, tacrolimus and mycophenolate mofetil. Eleven days after kidney transplantation the stem cell graft is thawed and infused to the recipient. If mixed donor chimerism is successfully maintained more than 6 months without rejection, then immunosuppression may be tapered off until complete discontinuation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-10-07.
Trial Details
NCT Number NCT05086003
Lead Sponsor Rabin Medical Center
Conditions Renal Transplantation
Enrollment 20 participants
Start Date 2016-01-19
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2021-10-28